TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1996621

Group type: EXPERIMENTAL
Intervention: Cortisol infusion (10 mg/h) after pretreatment with dexamethasone (4 mg/day) for 4 or 6 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg/day) for 4 or 6 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Potassium canrenoate (200 mg, at 0800 and 1700 h before experimental nights)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 18
Study: 6324934

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) 20 mg/m2 daily for the entire treatment duration.
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Sequential administration of Tamoxifen (TAM) 20 mg/m2 daily for 15 days followed by Medroxyprogesterone acetate 350 mg/m2 daily for the next 15 days.
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Sequential administration of Tamoxifen (TAM) and Medroxyprogesterone acetate.
Number of subjects: 79
Study: 30840307

Group type: EXPERIMENTAL
Intervention: 1 mg/kg ketamine (Group K1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg ketamine (Group K1.5)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2 mg/kg ketamine (Group K2)
Number of subjects: 60
Study: 29394975

Group type: EXPERIMENTAL
Intervention: Sofosbuvir and ribavirin combination therapy
Number of subjects: 196
Study: 25261491

Group type: EXPERIMENTAL
Intervention: Cut-out orthosis
Number of subjects: 46

Group type: COMPARATOR
Intervention: No orthosis
Number of subjects: 46
Study: 24578358

Group type: COMPARATOR
Intervention: Moderate alcohol consumption
Number of subjects: 11000

Group type: COMPARATOR
Intervention: Wine consumption
Number of subjects: 11000

Group type: COMPARATOR
Intervention: Heavy alcohol consumption
Number of subjects: 11000
Study: 22997785

Group type: EXPERIMENTAL
Intervention: Acupoint heat-sensitive moxibustion, 50 treatments over 3 months, 30 to 90 minutes each treatment.
Number of subjects: 64

Group type: COMPARATOR
Intervention: Seretide inhaler, one inhalation twice per day for 3 months.
Number of subjects: 64
Study: 20444448

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated pins (HA group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Stainless steel pins (steel group)
Number of subjects: 40
Study: 17854448

Group type: EXPERIMENTAL
Intervention: Exercise-based treatment designed to accelerate cerebellar development
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control data
Number of subjects: 0
Study: 15858811

Group type: EXPERIMENTAL
Intervention: Synchronized Intermittent Mandatory Ventilation (SIMV)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional Intermittent Mandatory Ventilation (IMV)
Number of subjects: 18
Study: 12539003

Group type: EXPERIMENTAL
Intervention: Aprotinin (high dose)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aprotinin (low dose)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aprotinin (both doses)
Number of subjects: 60
Study: 10759824

Group type: EXPERIMENTAL
Intervention: Electrodessication
Number of subjects: 0

Group type: COMPARATOR
Intervention: CO2 laser
Number of subjects: 0
Study: 8884643

Group type: EXPERIMENTAL
Intervention: 25% tetracycline fiber
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 2% minocycline gel
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 25% metronidazole gel
Number of subjects: 52

Group type: COMPARATOR
Intervention: Scaling and root planing alone
Number of subjects: 52
Study: 1852793

Group type: EXPERIMENTAL
Intervention: Fluoxetine (40-80 mg/d)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Maprotiline (50-150 mg/d)
Number of subjects: 65
Study: 6358700

Group type: EXPERIMENTAL
Intervention: Structured physical fitness program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Customary organized activities
Number of subjects: 0
Study: 31858234

Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT)
Number of subjects: 426

Group type: COMPARATOR
Intervention: No hormone therapy (No HT)
Number of subjects: 426
Study: 30453379

Group type: EXPERIMENTAL
Intervention: 19 G Flex needle
Number of subjects: 125

Group type: COMPARATOR
Intervention: 22 G needle
Number of subjects: 125
Study: 28216550

Group type: EXPERIMENTAL
Intervention: Fructose (F)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Sucrose (S)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Glucose (G)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Water (W)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Glucose + Fructose (C)
Number of subjects: 7
Study: 26390724

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEXA) 6 mg/m2
Number of subjects: 1064

Group type: COMPARATOR
Intervention: Methylprednisolone (MePRED) 60 mg/m2
Number of subjects: 1064

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEXA) in children younger than 14 years
Number of subjects: 1064

Group type: COMPARATOR
Intervention: Methylprednisolone (MePRED) in adolescents aged 14-18 years
Number of subjects: 1064
Study: 24100259

Group type: EXPERIMENTAL
Intervention: Aminophylline administration
Number of subjects: 0
Study: 21883954

Group type: EXPERIMENTAL
Intervention: Vardenafil ODT 10 mg
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 19214890

Group type: EXPERIMENTAL
Intervention: Lactulose/mannitol (L/M) ratio
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Saccharose excretion
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: AGA-IgA
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: AGA-IgG
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: EMA assay
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: L/M ratio in group A (n = 23)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: EMA in group B
Number of subjects: 47
Study: 17273647

Group type: EXPERIMENTAL
Intervention: Nutritional education (three two-hour meetings over three weeks)
Number of subjects: 80
Study: 15272100

Group type: EXPERIMENTAL
Intervention: St. John's wort (SJW) extract LI 160, 300 mg twice daily for 6 weeks
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study: 11384792

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) plus aerobic exercise plus usual and customary care
Number of subjects: 1356

Group type: EXPERIMENTAL
Intervention: Aerobic exercise plus usual and customary care
Number of subjects: 1356

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) plus usual and customary care
Number of subjects: 1356

Group type: COMPARATOR
Intervention: Usual and customary care alone
Number of subjects: 1356
Study: 9100744

Group type: EXPERIMENTAL
Intervention: Nurses viewing videotaped interviews of patients with different family structures (married mother, married with no children, divorced mother, divorced with no children, unmarried mother, unmarried with no children, remarried with spouse's children, remarried with no children)
Number of subjects: 0
Study: 8491438

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761 (50, 100, 150, or 200 mg)
Number of subjects: 42
Study: 3031225

Group type: EXPERIMENTAL
Intervention: Etoposide (arm C)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Etoposide (arm B)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Methotrexate (arm A)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Etoposide (arm C) for favorable performance status (0 + 1)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Methotrexate (arm A) for favorable performance status (0 + 1)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Etoposide (arm B) for favorable performance status (0 + 1)
Number of subjects: 288
Study: 29135347

Group type: EXPERIMENTAL
Intervention: High relative cerebral blood volume (rCBV)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Low hypoperfusion index ratio (HIR)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Relative cerebral blood volume (rCBV)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Lower relative cerebral blood volume (rCBV)
Number of subjects: 158
Study: 27821093

Group type: EXPERIMENTAL
Intervention: Inosine pranobex
Number of subjects: 463

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 463
Study: 24600651

Group type: EXPERIMENTAL
Intervention: 1.0 mL (0.3 mg/mL) recombinant human platelet-derived growth factor BB (rh-PDGF-BB) mixed with bovine or equine matrix
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 1.0 mL (0.3 mg/mL) recombinant human platelet-derived growth factor BB (rh-PDGF-BB) mixed with equine matrix
Number of subjects: 8
Study: 22903911

Group type: EXPERIMENTAL
Intervention: Expressive writing intervention (participants wrote about their deepest thoughts and feelings relating to their ambivalence)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control condition (participants wrote about how they had spent their time that day or week)
Number of subjects: 40
Study: 20353114

Group type: COMPARATOR
Intervention: Continuous wave electroacupuncture
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Rarefaction wave electroacupuncture
Number of subjects: 85
Study: 18583287

Group type: EXPERIMENTAL
Intervention: OPCAB with cTnT <1 ng/mL
Number of subjects: 1511

Group type: EXPERIMENTAL
Intervention: OPCAB with cTnT >=1 ng/mL
Number of subjects: 1511

Group type: COMPARATOR
Intervention: CCAB
Number of subjects: 1511
Study: 16982385

Group type: EXPERIMENTAL
Intervention: Teacher-led physical activity (TLPA) program
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Self-led physical activity (SLPA) program
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 14563343

Group type: EXPERIMENTAL
Intervention: Pravastatin 40mg
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study: 10937409

Group type: EXPERIMENTAL
Intervention: Hospital in the Home (HITH)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hospital admission (control group)
Number of subjects: 100
Study: 9014651

Group type: EXPERIMENTAL
Intervention: 1000 mg Ca as CaCO3, consumed between meals 5 days/week for 1 year
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 60
Study: 1569347

Group type: EXPERIMENTAL
Intervention: Fleroxacin, 400 mg, single oral dose
Number of subjects: 98

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (TMP‐SMZ), 160/800 mg, twice daily for 3 days
Number of subjects: 98
Study: 3902176

Group type: EXPERIMENTAL
Intervention: 90 mg diltiazem
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 60 mg diltiazem
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 30 mg diltiazem
Number of subjects: 16
Study: 30044935

Group type: EXPERIMENTAL
Intervention: Thawed plasma administration
Number of subjects: 501

Group type: COMPARATOR
Intervention: Standard-care resuscitation
Number of subjects: 501
Study: 28734146

Group type: EXPERIMENTAL
Intervention: Whole body diffusion-weighted MRI (WB-DWI/MRI)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Computed tomography (CT)
Number of subjects: 161
Study: 26148364

Group type: EXPERIMENTAL
Intervention: Ilioinguinal‐iliohypogastric block with 10 ml 0.5% ropivacaine from each side
Number of subjects: 164

Group type: COMPARATOR
Intervention: Transversus abdominis plane block with 20 ml 0.25% ropivacaine
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Both blocks
Number of subjects: 164
Study: 22785001

Group type: EXPERIMENTAL
Intervention: 3D Virtual Environment (VE)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Physical Environment (PE)
Number of subjects: 32
Study: 20363905

Group type: EXPERIMENTAL
Intervention: Distraction-inhibiting implementation intention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Response-facilitating implementation intention
Number of subjects: 0
Study: 18186265

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation (standard of care)
Number of subjects: 0
Study: 15940125

Group type: EXPERIMENTAL
Intervention: Internet-based monitoring
Number of subjects: 300
Study: 14669282

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT) after hyper-CVAD regimen; high-dose cyclophosphamide (120 mg/kg), total body irradiation, and ASCT.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Patients with M. D. Anderson Lymphoma Tumor Score (TS) ≤ 1 at diagnosis or transplantation.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Patients with β2-microglobulin (β2m) level ≤ 3 mg/L at diagnosis or transplantation.
Number of subjects: 33
Study: 10097996

Group type: EXPERIMENTAL
Intervention: TOM test scores in normal children (n = 70)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: TOM test in young children
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: TOM test in older children
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: TOM test in normal children (n = 12)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: TOM test in children with PDDs (n = 10)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: TOM test in children with PDDs (n = 20)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: TOM test scores
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: TOM test
Number of subjects: 70
Study: 8901129

Group type: EXPERIMENTAL
Intervention: 30 mg morphine hydrochloride as Vendal retard film tablets
Number of subjects: 24

Group type: COMPARATOR
Intervention: 30 mg morphine sulphate as Mundidol retard film tablets
Number of subjects: 24
Study: 1794831

Group type: EXPERIMENTAL
Intervention: Gelomyrtol forte
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6621017

Group type: EXPERIMENTAL
Intervention: Electroacoustically similar hearing aids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electroacoustically heterogeneous hearing aids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard monosyllabic word lists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparative hearing aid evaluation
Number of subjects: 0
Study: 31892355

Group type: EXPERIMENTAL
Intervention: SuperPath
Number of subjects: 4

Group type: COMPARATOR
Intervention: PLA
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 4
Study: 30557342

Group type: EXPERIMENTAL
Intervention: CTRP3
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: CTRP9
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: MCP-1
Number of subjects: 86
Study: 27095446

Group type: EXPERIMENTAL
Intervention: Oral fat load test meal (OFTT) with 0.7 g fat/kg body weight (12% SFA, 10% PUFA, 43% MUFA, 10% protein, 25% carbohydrates)
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Oral fat load test meal (OFTT)
Number of subjects: 1002
Study: 24767004

Group type: EXPERIMENTAL
Intervention: Cognitive control therapy (CCT) + active transcranial direct current stimulation (tDCS)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Cognitive control therapy (CCT)
Number of subjects: 37
Study: 21805294

Group type: EXPERIMENTAL
Intervention: Celastrus orbiculatus extract (COE) at concentrations of 10, 20, 40, 80, and 160 μg/mL
Number of subjects: 0
Study: 20667751

Group type: EXPERIMENTAL
Intervention: A-V impulse technology (A-V)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Compression stocking (CS)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Re-operation
Number of subjects: 36
Study: 17443478

Group type: EXPERIMENTAL
Intervention: pegylated IFN‐alfa‐2a
Number of subjects: 133

Group type: COMPARATOR
Intervention: IFN‐alfa‐2a
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Hematopoietic growth factors
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Dose modifications for nonhematologic toxicity
Number of subjects: 133
Study: 15309001

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 4902

Group type: COMPARATOR
Intervention: No Aspirin
Number of subjects: 4902

Group type: EXPERIMENTAL
Intervention: Withheld Aspirin
Number of subjects: 4902
Study: 12040470

Group type: EXPERIMENTAL
Intervention: G-CSF (5 microg/kg starting on the day of infusion)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: G-CSF (5 microg/kg starting five days later)
Number of subjects: 241

Group type: COMPARATOR
Intervention: No G-CSF (Control Group)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: G-CSF (both arms A and B)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: G-CSF on day 0 vs day +5
Number of subjects: 241
Study: 11352697

Group type: EXPERIMENTAL
Intervention: Interferon-alpha
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study: 9408713

Group type: EXPERIMENTAL
Intervention: Individual subject random assignment clinical trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observational studies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Community randomized trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical trials of pharmacologic agents
Number of subjects: 0
Study: 8505479

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: COMPARATOR
Intervention: Non-ADHD controls
Number of subjects: 26
Study: 3555036

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin therapy (750 to 2,250 mg daily, mean 1,800 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Combination therapy (tobramycin or azlocillin)
Number of subjects: 18
Study: 31181990

Group type: EXPERIMENTAL
Intervention: Immediate Release (IR) formulation of cilostazol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sustained Release (SR) formulation of cilostazol
Number of subjects: 0
Study: 29374327

Group type: EXPERIMENTAL
Intervention: Local tranexamic acid
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conventional hemostasis measures (Control)
Number of subjects: 37
Study: 28044948

Group type: EXPERIMENTAL
Intervention: ERAS Group
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard Group
Number of subjects: 83
Study: 23906190

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg) from 1 day before to 14 days after surgery
Number of subjects: 236

Group type: COMPARATOR
Intervention: No tamsulosin treatment (control group)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Tamsulosin treatment
Number of subjects: 236

Group type: COMPARATOR
Intervention: Tamsulosin treatment and control
Number of subjects: 236
Study: 23697477

Group type: EXPERIMENTAL
Intervention: Pharmaceutical counseling of hospital medical staff and additional information in the discharge letter for the PCP
Number of subjects: 240
Study: 20977584

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: 50 mg LC15-0444
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: 100 mg LC15-0444
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: 200 mg LC15-0444
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: All doses of LC15-0444
Number of subjects: 145
Study: 18940296

Group type: EXPERIMENTAL
Intervention: Group-based high-intensity aerobic interval training (exercise group, n = 40), exercised twice a week for 4 months plus 4 consultations with a CHF nurse.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (n = 40), no specific intervention mentioned.
Number of subjects: 80
Study: 15794797

Group type: EXPERIMENTAL
Intervention: Laparoscopic donor nephrectomy (LDN)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Open donor nephrectomy (ODN)
Number of subjects: 200
Study: 12641613

Group type: EXPERIMENTAL
Intervention: Spatone Iron‐Plus (48 ml)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 10595595

Group type: EXPERIMENTAL
Intervention: UL-TG 307 (24 mg daily)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 8767527

Group type: EXPERIMENTAL
Intervention: 2-chlorodeoxyadenosine (2-CDA)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fludarabine (FAMP)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Chlorambucil (CLB)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 2-CDA and FAMP
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: FAMP and 2-CDA
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Purine analogs
Number of subjects: 80
Study: 1678570

Group type: EXPERIMENTAL
Intervention: 0.1% bunazosin hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (contralateral eyes)
Number of subjects: 0
Study: 30551783

Group type: EXPERIMENTAL
Intervention: Forearm band
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Elbow sleeve
Number of subjects: 50

Group type: COMPARATOR
Intervention: No brace
Number of subjects: 50
Study: 28304200

Group type: EXPERIMENTAL
Intervention: ADVANCE technique
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 67
Study: 26603970

Group type: EXPERIMENTAL
Intervention: African ancestry RGA increase (0.10)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: European ancestry RGA increase (0.10)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: African RGA tertiles (6%‐66%)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: African RGA tertiles (67%‐86%)
Number of subjects: 149
Study: 25052785

Group type: EXPERIMENTAL
Intervention: In-prison substance use and depression treatments
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Post-release support network
Number of subjects: 60
Study: 21928226

Group type: EXPERIMENTAL
Intervention: Prolonged prednisolone therapy (5-month)
Number of subjects: 80
Study: 19497441

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 2111
Study: 17660645

Group type: EXPERIMENTAL
Intervention: Airotor
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Carisolv
Number of subjects: 150

Group type: COMPARATOR
Intervention: Hand instruments
Number of subjects: 150
Study: 15222602

Group type: EXPERIMENTAL
Intervention: Therapeutic touch treatments (6 sessions)
Number of subjects: 0
Study: 11755284

Group type: EXPERIMENTAL
Intervention: Medical food bar enriched with L-arginine and other nutrients
Number of subjects: 36
Study: 9842980

Group type: EXPERIMENTAL
Intervention: Test formulation of cisapride (10 mg per unit, 20 mg total dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference formulation of cisapride (10 mg per unit, 20 mg total dose)
Number of subjects: 0
Study: 7856298

Group type: EXPERIMENTAL
Intervention: 10 micrograms hepatitis B vaccine
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: 5 micrograms hepatitis B vaccine
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Both dosages of hepatitis B vaccine
Number of subjects: 174
Study: 2504532

Group type: EXPERIMENTAL
Intervention: Levothroid
Number of subjects: 18

Group type: COMPARATOR
Intervention: Synthroid
Number of subjects: 18